Advertisement

The ameliorative effect of AST2017-01 in an ovalbumin-induced allergic rhinitis animal model

  • Hee-Yun Kim
  • Hyunwoo Jee
  • Jun-Ho Yeom
  • Hyun-Ja JeongEmail author
  • Hyung-Min KimEmail author
Original Research Paper
  • 23 Downloads

Abstract

Objective

AST2017-01 is developed to be used for treatment and prevention of allergic diseases and composed of processed-Cordyceps militaris and processed-Rumex crispus. But, effect of AST2017-01 remains unclear in an allergic rhinitis (AR). So, this study aimed to explore the effects of AST2017-01 in ovalbumin (OVA)-induced AR animal model.

Methods

OVA-induced AR animals were orally administered AST2017-01 and chrysophanol, an active component of AST2017-01 for 10 days.

Results

In mice with AR, AST2017-01 and chrysophanol markedly decreased number of rubs, IgE, histamine, thymic stromal lymphopoietin, tumor necrosis factor-α, interleukin (IL)-1β, IL-4, IL-5, and IL-13 in serum or nasal mucosa tissues. Moreover, activities and protein levels of caspase-1 were markedly diminished by oral administration of AST2017-01 and chrysophanol. Declines of macrophage inflammatory protein-2, intercellular adhesion molecules-1, eosinophil, and mast cells were also noted in nasal mucosa tissues of AST2017-01 and chrysophanol groups.

Conclusions

Taken together, these findings indicate that AST2017-01 has an anti-allergic effect as a therapeutic agent or functional food for treating and preventing AR.

Keywords

AST2017-01 Chrysophanol Allergic rhinitis animal model Macrophage inflammatory protein-2 Intercellular adhesion molecules-1 Infiltration 

Notes

Funding

This work was supported by Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, Forestry and Fisheries (IPET) through High Value-added Food Technology Development Program, funded by Ministry of Agriculture, Food and Rural Affairs (MAFRA) (116169-3).

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest.

Ethical standards

All procedures performed in studies involving murine tissues were in accordance with the ethical standards of the institution and/or national research.

References

  1. 1.
    Skoner DP. Allergic rhinitis: definition, epidemiology, pathophysiology, detection, and diagnosis. J Allergy Clin Immunol. 2001;108:2–8.CrossRefGoogle Scholar
  2. 2.
    Meltzer EO, Blaiss MS, Derebery MJ, Mahr TA, Gordon BR, Sheth KK, et al. Burden of allergic rhinitis: results from the pediatric allergies in America survey. J Allergy Clin Immunol. 2009;124:43–70.CrossRefGoogle Scholar
  3. 3.
    Fineman SM. The burden of allergic rhinitis: beyond dollars and cents. Ann Allergy Asthma Immunol. 2002;88:2–7.CrossRefGoogle Scholar
  4. 4.
    Howarth PH, Persson CG, Meltzer EO, Jacobson MR, Durham SR, Silkoff PE. Objective monitoring of nasal airway inflammation in rhinitis. J Allergy Clin Immunol. 2005;115:414–41.CrossRefGoogle Scholar
  5. 5.
    Naclerio RM, Proud D, Togias AG, Adkinson NF, Meyers DA, Kagey-Sobotka A, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med. 1985;313:e65–70.CrossRefGoogle Scholar
  6. 6.
    Blanc PD, Trupin L, Earnest G, Katz PP, Yelin EH, Eisner MD. Alternative therapies among adults with a reported diagnosis of asthma or rhinosinusitis: data from a population-based survey. Chest. 2001;120:1461–7.CrossRefGoogle Scholar
  7. 7.
    Markham AW, Wilkinson JM. Complementary and alternative medicines (CAM) in the management of asthma: an examination of the evidence. J Asthma. 2004;41:131–9.CrossRefGoogle Scholar
  8. 8.
    Jang JB, Kim TY, Jeong HJ, Kim HM. Validation of chrysophanol and cordycepin as marker compounds for standardization of a new herbal mixture AST2017-01. TANG. 2017;7:e14.Google Scholar
  9. 9.
    Wada T, Sumardika IW, Saito S, Ruma IMW, Kondo E, Shibukawa M, et al. Identification of a novel component leading to anti-tumor activity besides the major ingredient cordycepin in Cordyceps militaris extract. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1061–1062:209–19.CrossRefGoogle Scholar
  10. 10.
    Hsu CH, Sun HL, Sheu JN, Ku MS, Hu CM, Chan Y, et al. Effects of the immunomodulatory agent Cordyceps militaris on airway inflammation in a mouse asthma model. Pediatr Neonatol. 2008;49:171–8.CrossRefGoogle Scholar
  11. 11.
    Garodia P, Ichikawa H, Malani N, Sethi G, Aggarwal BB. From ancient medicine to modern medicine: ayurvedic concepts of health and their role in inflammation and cancer. J Soc Integr Oncol. 2007;5:25–37.CrossRefGoogle Scholar
  12. 12.
    Lee SS, Kim DH, Yim DS, Lee SY. Anti-inflammatory, analgesic and hepatoprotective effect of semen of Rumex crispus. Korean J Pharmacogn. 2007;38:334–8.Google Scholar
  13. 13.
    Park DH, Jeong GT, Lee GM. Study of antimicrobial and antioxidant activities of Rumex crispus extract. Korean Chem Eng Res. 2006;44:81–6.Google Scholar
  14. 14.
    Shiwani S, Singh NK, Wang MH. Carbohydrase inhibition and anti-cancerous and free radical scavenging properties along with DNA and protein protection ability of methanolic root extracts of Rumex crispus. Nutr Res Pract. 2012;6:389–95.CrossRefGoogle Scholar
  15. 15.
    Kim HY, Jeong HJ, Kim HM. Anti-allergic and anti-inflammatory effects of the Bcl-2 inhibitor ABT-737 on experimental allergic rhinitis models. Eur J Pharmacol. 2018;833:34–43.CrossRefGoogle Scholar
  16. 16.
    Kim HY, Han NR, Kim HM, Jeong HJ. The iron chelator and anticancer agent Dp44mT relieves allergic inflammation in mice with allergic rhinitis. Inflammation. 2018;41:1744–54.CrossRefGoogle Scholar
  17. 17.
    Jeong HJ, Kim HY, Kim HM. Molecular mechanisms of anti-inflammatory effect of chrysophanol, an active component of AST2017-01 on atopic dermatitis in vitro models. Int Immunopharmacol. 2018;54:238–44.CrossRefGoogle Scholar
  18. 18.
    Han NR, Moon PD, Yoo MS, Ryu KJ, Kim HM, Jeong HJ. Regulatory effects of chrysophanol, a bioactive compound of AST2017-01 in a mouse model of 2,4-dinitrofluorobenzene-induced atopic dermatitis. Int Immunopharmacol. 2018;62:220–6.CrossRefGoogle Scholar
  19. 19.
    Urata Y, Osuga Y, Izumi G, Takamura M, Koga K, Nagai M, et al. Interleukin-1β stimulates the secretion of thymic stromal lymphopoietin (TSLP) from endometrioma stromal cells: possible involvement of TSLP in endometriosis. Hum Reprod. 2012;27:3028–35.CrossRefGoogle Scholar
  20. 20.
    Lee EB, Kim KW, Hong JY, Jee HM, Sohn MH, Kim KE. Increased serum thymic stromal lymphopoietin in children with atopic dermatitis. Pediatr Allergy Immunol. 2010;21:e457–60.CrossRefGoogle Scholar
  21. 21.
    Liu YJ. Thymic stromal lymphopoietin: master switch for allergic inflammation. J Exp Med. 2006;203:269–73.CrossRefGoogle Scholar
  22. 22.
    Zheng T, Yu J, Oh MH, Zhu Z. The atopic march: progression from atopic dermatitis to allergic rhinitis and asthma. Allergy Asthma Immunol Res. 2011;3:67–73.CrossRefGoogle Scholar
  23. 23.
    Lamkanfi M, Kanneganti TD, Franchi L, Núñez G. Caspase-1 inflammasomes in infection and inflammation. J Leukoc Biol. 2007;82:220–5.CrossRefGoogle Scholar
  24. 24.
    Proost P, Wuyts A, van Damme J. The role of chemokines in inflammation. Int J Clin Lab Res. 1996;26:211–23.CrossRefGoogle Scholar
  25. 25.
    Moser B, Willimann K. Chemokines: role in inflammation and immune surveillance. Ann Rheum Dis. 2004;63:ii84–9.CrossRefGoogle Scholar
  26. 26.
    Romagnani S. Cytokines and chemoattractants in allergic inflammation. Mol Immunol. 2002;38:881–5.CrossRefGoogle Scholar
  27. 27.
    Deo SS, Mistry KJ, Kakade AM, Niphadkar PV. Role played by Th2 type cytokines in IgE mediated allergy and asthma. Lung India. 2010;27:66–71.CrossRefGoogle Scholar
  28. 28.
    Coffman RL, Seymour BW, Hudak S, Jackson J, Rennick D. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science. 1989;45:308–10.CrossRefGoogle Scholar
  29. 29.
    Grünig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 1998;282:2258–61.CrossRefGoogle Scholar
  30. 30.
    Conti P. Impact of cytokines in mast cells allergic inflammation. Int Trends Immuno. 2013;1:5–16.Google Scholar
  31. 31.
    Subramanian N, Bray MA. Interleukin 1 releases histamine from human basophils and mast cells in vitro. J Immunol. 1987;138:271–5.Google Scholar
  32. 32.
    Thomas PS. Tumor necrosis factor-alpha: the role of this multifunctional cytokine in asthma. Immunol Cell Biol. 2001;79:132–40.CrossRefGoogle Scholar
  33. 33.
    Allakhverdi Z, Comeau MR, Jessup HK, Yoon BR, Brewer A, Chartier S, et al. Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells. J Exp Med. 2007;204:253–8.CrossRefGoogle Scholar
  34. 34.
    Nouri HR, Karkhah A, Mohammadzadeh I, Sankian M. Elevated caspase–1 activity and IL–1β expression are associated with the IPAF inflammasome in an experimental model of allergy. Mol Med Rep. 2016;13:3356–62.CrossRefGoogle Scholar
  35. 35.
    Kong F, Ye B, Lin L, Cai X, Huang W, Huang Z. Atorvastatin suppresses NLRP3 inflammasome activation via TLR4/MyD88/NF-κB signaling in PMA-stimulated THP-1 monocytes. Biomed Pharmacother. 2016;82:167–72.CrossRefGoogle Scholar
  36. 36.
    Choi YH, Jin GY, Li LC, Yan GH. Inhibition of protein kinase C delta attenuates allergic airway inflammation through suppression of PI3K/Akt/mTOR/HIF-1 alpha/VEGF pathway. PLoS One. 2013;8:e81773.CrossRefGoogle Scholar
  37. 37.
    Minai-Fleminger Y, Levi-Schaffer F. Mast cells and eosinophils: the two key effector cells in allergic inflammation. Inflamm Res. 2009;58:631–8.CrossRefGoogle Scholar
  38. 38.
    Bischoff SC. Role of mast cells in allergic and non-allergic immune responses: comparison of human and murine data. Nat Rev Immunol. 2007;7:93–104.CrossRefGoogle Scholar
  39. 39.
    Shakoory B, Fitzgerald SM, Lee SA, Chi DS, Krishnaswamy G. The role of human mast cell-derived cytokines in eosinophil biology. J Interferon Cytokine Res. 2004;24:271–81.CrossRefGoogle Scholar
  40. 40.
    Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med. 2012;18:716–25.CrossRefGoogle Scholar
  41. 41.
    Gangur V, Oppenheim JJ. Are chemokines essential or secondary participants in allergic responses? Ann Allergy Asthma Immunol. 2000;84:569–81.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Pharmacology, College of Korean MedicineKyung Hee UniversitySeoulRepublic of Korea
  2. 2.Department of Science in Korean Medicine, Graduate SchoolKyung Hee UniversitySeoulRepublic of Korea
  3. 3.Department of BiotechnologyHoseo UniversityAsanRepublic of Korea
  4. 4.Division of Food and Pharmaceutical EngineeringHoseo UniversityAsanRepublic of Korea

Personalised recommendations